ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment and tocilizumab"

  • Abstract Number: 460 • 2013 ACR/ARHP Annual Meeting

    Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis

    Felicity Buckley1, Axel Finckh2, Thomas W.J. Huizinga3, Fred Dejonckheere4 and Jeroen P. Jansen1, 1MAPI Consultancy, Boston, MA, 2Department of Medical Specialities, University of Geneva, Geneva, Switzerland, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4F. Hoffmann-La Roche Ltd, Basel, Switzerland

    Background/Purpose: To compare ACR responses of novel DMARDs as monotherapy or in combination with methotrexate (MTX), including subcutaneous (SC) abatacept and SC tocilizumab (TCZ), in…
  • Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition

    Cem Gabay1, Katie Tuckwell2, Jennifer Green2, Micki Klearman3 and Arthur Kavanaugh4, 1SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 2Roche, Welwyn Garden City, United Kingdom, 3Roche, South San Francisco, CA, 4University of California, San Diego, La Jolla, CA

    Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
  • Abstract Number: 463 • 2012 ACR/ARHP Annual Meeting

    Drug Survival, Efficacy and Predictors for Survival On Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register

    Helena Forsblad-d'Elia1, Karin Bengtsson1, Lars-Erik Kristensen2 and Lennart TH Jacobsson1, 1Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 2Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden

    Background/Purpose: To evaluate drug survival, clinical response and predictors for drug survival for tocilizumab in patients with rheumatoid arthritis (RA) with inadequate response and/or adverse…
  • Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting

    Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients

    Cesar Vargas-Serafin1, Luis Aguilar-Lozano1, Jorge Padilla-Ibarra1, Carlos Sandoval-Castro1, Jose Dionisio Castillo-Ortiz1, Jorge Morales-Torres2, Claudia Hernandez2 and Cesar Ramos-Remus1, 1Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, 2Rheumatology, Hospital Aranda de la Parra, Leon, Mexico

    Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…
  • Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting

    Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis

    Felicity Buckley1, Axel Finckh2, Thomas W. Huizinga3, Fred Dejonckheere4 and Jeroen P. Jansen1, 1MAPI Consultancy, Boston, MA, 2Rhumatology, University Hospital of Geneva, Geneva, Switzerland, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4F. Hoffmann-La Roche Ltd, Basel, Switzerland

    Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
  • Abstract Number: 1662 • 2012 ACR/ARHP Annual Meeting

    Anti-IL-6 Therapy Impairs Intestinal Repair Through Inhibition of Epithelial Proliferation After Injury

    Kristine Kuhn1, Hiroyuki Miyoshi2, Nicholas A. Manieri2, Nicole P. Malvin2, Vinieth Bijanki2, Paul Allen2 and Thaddeus S. Stappenbeck2, 1Internal Medicine, Washington University School of Medicine, St. Louis, MO, 2Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

    Background/Purpose: Inhibition of IL-6 is used for treatment of rheumatoid arthritis and now being investigated as biologic therapy for a wide variety of autoimmune conditions,…
  • Abstract Number: 1640 • 2012 ACR/ARHP Annual Meeting

    Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years

    Mark C. Genovese1, Anthony Sebba2, Andrea Rubbert-Roth3, Juan José Scali4, Rieke Alten5, Joel M. Kremer6, Laura Pitts7, Emma Vernon7 and Ronald F. van Vollenhoven8, 1Division of Rheumatology, Stanford University, Palo Alto, CA, 2University of South Florida, Tampa, FL, 3University of Cologne, Cologne, Germany, 4Durand University Hospital, Buenos Aires, Argentina, 5Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 6Center for Rheumatology, Albany Medical College, Albany, NY, 7Roche, Welwyn Garden City, United Kingdom, 8Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Tocilizumab (TCZ)—an IL-6 receptor inhibitor—has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving physical function in rheumatoid arthritis (RA) patients (pts). This…
  • Abstract Number: 1302 • 2012 ACR/ARHP Annual Meeting

    Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis

    Marie Kostine1, Thomas Barnetche2, Elodie Ardouin3, Marlene Joly4, Emilie Rabois5, Baptiste Glace Sr.6, Delphine Nigon7, Thierry Schaeverbeke8 and Christophe Richez9, 1Rheumatology, CHU Pellegrin, Bordeaux, France, 2Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, 3Rheumatology, Limoges University Hospital, Limoges, France, 4Rheumatology, Montpellier University Hospital, Montpellier, France, 5Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 6Rheumatology, Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, 7CHU Purpan, Toulouse, France, 8Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, 9Hôpital Pellegrin and Université Victor Segalen Bordeaux, France

    Background/Purpose: A reduction in peripheral blood neutrophils count is usually observed with the anti-interleukin (IL) 6 receptor antibody tocilizumab. This often appears few days after…
  • Abstract Number: 1271 • 2012 ACR/ARHP Annual Meeting

    Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry

    HC Leffers1, Mikkel Østergaard1, Bente Glintborg2, Niels Steen Krogh3, Ulrik Tarp4, Tove Lorenzen5, Annette Hansen6, Michael Sejer Hansen7, Lene Dreyer2, Martin S. Jakobsen2 and Merete Lund Hetland8, 1DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, 2DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, 3ZiteLab ApS, Copenhagen, Denmark, 4Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 5Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, 6Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, 7Gildhøj Privathospital, Copenhagen, Denmark, 8DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark

    Background/Purpose: Abatacept and tocilizumab have been shown to be efficacious for the treatment of rheumatoid arthritis (RA), even in patients refractory to tumor necrosis factor…
  • Abstract Number: 823 • 2012 ACR/ARHP Annual Meeting

    Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis

    Karine Briot1, Thierry Schaeverbeke2, Fabien Etchepare3, Philippe Gaudin4, Aleth Perdriger5, Muriel Vray6, Stephanie Rouanet7, Ghislaine Steinberg8 and Christian Roux1, 1Cochin hospital, Paris Descartes University, Paris, France, 2Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, 3G.H. Pitié-Salpêtrière, Paris, France, 4Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 5Rheumatology, Hôpital Sud, Rennes, France, 6Institut Pasteur, Paris, France, 7Medical Department, Roche, Boulogne-Billancourt, France, 8Medical Department, Roche, Neuilly sur Seine, France

    Background/Purpose: The anti-IL6-R antibody tocilizumab (TCZ) is an effective treatment of rheumatoid arthritis (RA). Previous studies showed that TCZ has a positive effect on bone…
  • Abstract Number: 772 • 2012 ACR/ARHP Annual Meeting

    Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study

    Arthur Kavanaugh1, Paul Emery2, Ronald F. van Vollenhoven3, Ara H. Dikranian4, Rieke Alten5, Micki Klearman6, David Musselman7, Sunil Agarwal7, Jennifer Green8 and Cem Gabay9, 1UCSD School of Medicine, La Jolla, CA, 2Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 3Karolinska Institute, Stockholm, Sweden, 4San Diego Arthritis Medical Clinic, San Diego, CA, 5Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 6Roche, South San Francisco, CA, 7Genentech Inc, South San Francisco, CA, 8Roche, Welwyn Garden City, United Kingdom, 9Rheumatology, Geneva University Hospitals, Geneva, Switzerland

    Background/Purpose: Approximately one-third of RA pts treated with biologics receive them as monotherapy (ie, without other DMARDs).1-3 Although tocilizumab (TCZ), an IL-6 receptor inhibitor, has…
  • Abstract Number: 454 • 2012 ACR/ARHP Annual Meeting

    Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months

    Graeme Jones1, Anthony Sebba2, Denise Lepley3, Jenny Devenport4, Corrado Bernasconi5, Devi Smart6, Chiedzo Mpofu7 and Juan J. Gomez-Reino8, 1Musculoskeletal, Menzies Research Institute Tasmania, Hobart, Australia, 2University of South Florida, Tampa, FL, 3Medical Affairs Immunology, Genentech, South San Francisco, CA, 4Genentech, South San Francisco, CA, 5Consultant, Basel, Switzerland, 6Roche, Welwyn Garden City, United Kingdom, 7Roche, Basel, Switzerland, 8Rheumatology, Hospital Clinico Universitario, Santiago, Spain

    Background/Purpose: Treatment with tocilizumab (TCZ) monotherapy has been studied in 3 randomized clinical trials: AMBITION,1 ACT-RAY,2 and ADACTA.3 AMBITION1  was the first trial to demonstrate…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology